Ask AI

APP-Led Management of HER2-, TROP2-, and B7-H3–Directed ADC Adverse Events in Solid Tumors: Practical Strategies for the Clinic

Enhance your ability to anticipate, identify, grade, triage, and manage adverse events associated with HER2-, TROP2-, and emerging B7-H3–directed ADC therapies in patients with breast cancer, lung cancer, and other solid tumors to optimize care through an expert-authored ClinicalThought commentary and certified on-demand webcast with accompanying downloadable slides.

Share

Program Content

Events

  • Live Event
    APP-Led Management of HER2-, TROP2-, and B7-H3–Directed ADC Adverse Events in Solid Tumors: Practical Strategies for the Clinic
    Congratulations: You achieved a completion on 04/09/2022

    You can enroll in the following live event(s) on this topic.

Activities

APP-Led Management of ADC AEs in Solid Tumors
APP-Led Management of HER2-, TROP2-, and B7-H3–Directed ADC Adverse Events in Solid Tumors: Practical Strategies for the Clinic
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 12, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Supporters

This activity is supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme LLC